New data: Hospital readmission among NVAF hospitalized patients treated with new oral anticoagulantsData from a real-world analysis provided an early view of hospital readmissions among hospitalized nonvalvular atrial fibrillation (NVAF) patients treated with new oral anticoagulants (NOACs).
ACC: NVAF patients at high risk for stroke may be undertreatedMany nonvalvular atrial fibrillation (NVAF) patients at high risk for stroke may be undertreated, according to poster presentation sessions at the American College of Cardiology (ACC) 64th Annual Scientific Session in San Diego, Calif.
Fondaparinux beats heparin in major studyThe anticoagulant medication Fondaparinux (Arixtra) was associated with reduced major bleeding events and improved survival, compared to low-molecular-weight heparin (LMWH) in a large randomized clinical trial involving patients with non–ST-segment elevation myocardial infarction (NSTEMI), according to a new study.
Factor Xa inhibitor approved to reduce stroke risk in AF patientsThe factor Xa inhibitor edoxaban (Savaysa, Daiichi Sankyo) has been approved by FDA to lower the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (AF).
New Anticoagulants for AF (VIDEO)The Doctor's Channel Video: Results of a new meta-analysis indicate that for patients with atrial fibrillation, treatment with one of the new oral anticoagulants rather than warfarin is more effective for preventing stroke and less risky in terms of intracranial bleeding.
Can dabigatran be used in pregnant women?
Can dabigatran be used in pregnant women?Using dabigatran anticoagulation treatment for pregnant women could potentially affect fetal blood coagulation, according to a study published in Obstetrics & Gynecology. Dabigatran may cross the placenta to the fetus.
ISMP calls for FDA action on dabigatran bleeding riskThe high risk of bleeding in patients taking the anticoagulant dabigatran (Pradaxa) has been a major problem that the manufacturer and health experts have been trying to find solutions for over the last four years. Sixteen percent of patients experienced a bleed in one year, including 3.3% who had bleeds that required emergency medical treatment, according to one clinical trial.
Warfarin may benefit Afib patients with CKD after heart attackWarfarin use may be safe following a heart attack in patients with both atrial fibrillation and chronic kidney disease, according to a Swedish study of more than 24,000 patients.
Oct. 4 deadline for comments on plan for ADE prevention
Oct. 4 deadline for comments on plan for ADE preventionThe Office of Disease Prevention and Health Promotion under the Department of Health and Human Services (HHS) is calling for public review and comments on its draft plan to reduce adverse drug events that are preventable. The deadline is Friday, Oct. 4 to email feedback to